Dan Lewis has had a long career working in the health care industry, both as a managed care Pharmacy Director and in the pharmaceutical industry. 

Dan spent ten-plus years in managed care Pharmacy Director roles, at Humana HealthChicago, Ochsner Health Plan, and Dean Health Plan. His responsibilities included formulary development and management, network development, rebate contracting, specialty pharmacy management, and utilization management.

In his pharmaceutical industry roles at UCB, Takeda, and Fujisawa Healthcare, he was responsible for managed care account  strategy development and management, contract negotiation, and managed care marketing.  Customers included commercial insurers, state and federal government accounts, wholesalers, and specialty pharmacy accounts. Over the past 10 years, he has been directly involved in with medical benefit buy-and-bill strategy development and execution within medical organizations providing direct patient care.

Dan has recently been focused on initiatives geared to expanding specialty and out-patient clinic practices based on overall communication programs, patient retention, and effective management of public and private third party payors.

Dan holds as B.S. degree in Pharmacy from Drake University, and an M.B.A. from DePaul University.

Jay Welsh brings over 30 years of expertise in the biopharma industry with a deep understanding of the US healthcare market and what's required to build and implement effective commercialization strategies. He has launched multiple start-up companies; collaborated on deals valued >$1 billion and launched over 20 specialty products.

Beginning his career in sales, sales management and leadership development at Forest Labs (now Abbvie), Jay led sales teams in multiple product launches and played a pivotal role in establishing Forest’s hospital and specialty sales organizations.

He joined Ovation Pharmaceuticals in 2003 as one of its initial 25 employees. At Ovation (acquired by Lundbeck in 2009), he held senior marketing and sales roles and helped launch multiple drugs and biologics for rare and ultra-rare diseases. At Recordati Rare Diseases, he was an instrumental member of the leadership team tasked with building the commercial organization and marketing several specialty/Orphan products. This was later replicated at Altathera and again at HRA Pharma Rare Diseases. At HRA, Jay revitalized a legacy therapeutic and diagnostic acquired from BMS and Novartis respectively, transitioning them to a limited distribution network while increasing patient access, advocacy outreach and physician education.

Jay’s work with start-ups has enabled him to extend into areas such as portfolio assessment and valuation, leading to several successful transactions such as licensing Linsitinib from Astellas as part of a $35 million Series A investment as an advisor to Sling Therapeutics, and negotiating the North American commercial rights for XTMAB-16, partnering with Xentria while at Meitheal Pharmaceuticals in a deal valued near $700 million.

Jay holds a B.A. in Biology from William Jewell College and an M.B.A. from the University of Chicago Booth School of Business.